Advisors LLC Orbimed sold 33,356 shares of Sionna Therapeutics for $1,486,009.80, reducing indirect ownership to 3,561,655 shares on Dec. 24, 2025. The sale matched recent disposals’ median size, attributing all shares to OrbiMed Private Investments VIII, LP, without any direct holdings involved. The transaction was part of a series of large disposals in 2025, as available capacity approached zero.
The sale represented 0.93% of Advisors LLC Orbimed’s indirect holdings, with all shares sold indirectly through OrbiMed Private Investments VIII, LP, and no direct holdings affected. The 33,356-share sale aligned with past dispositions, hinting at a strategic approach to selling as holdings diminish, with no direct ownership pre or post-transaction. The timing and size of the sale reflected the shrinking capacity for large-scale disposals in 2025.
Sionna Therapeutics focuses on developing treatments for cystic fibrosis, aiming to normalize the CFTR protein’s function. The company caters to cystic fibrosis patients and rare genetic disease specialists. With a strategic emphasis on proprietary science and targeted therapies, Sionna positions itself to compete in the rare disease biopharmaceutical sector. The company raised $191 million in its IPO and made progress with experimental treatments for cystic fibrosis.
Positive phase 1 results for Sionna Therapeutics’ lead candidates were announced in June, with a phase 2 trial underway for cystic fibrosis patients. The company targets the normalization of CFTR protein function, aiming to address unmet medical needs in the cystic fibrosis patient population. While progress has been made, further clinical trials are needed to confirm the benefits for cystic fibrosis patients.
The sale of shares by Advisors LLC Orbimed served as a supplement to their income, with over 3.5 million shares retained. Sionna Therapeutics continues to develop treatments for cystic fibrosis, with positive results from phase 1 trials but further trials are ongoing. The company’s strategic focus on proprietary science and targeted therapies positions it to compete in the rare disease biopharmaceutical sector.
Read more at Yahoo Finance: A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million